Semaglutide and GLP-1 Peptides: How They Actually Work (2026 Guide)
Educational guide for research and informational purposes only. Not medical advice.
Semaglutide has become the most discussed weight management compound in mainstream medicine. The conversation around it is often either oversimplified ("it makes you not hungry") or buried in clinical language. This guide cuts through both — explaining the actual biology, the pharmacokinetics, the reconstitution math, and what separates GLP-1 therapy from every other fat loss approach that came before it.
What GLP-1 Actually Is
GLP-1 (Glucagon-Like Peptide-1) is an endogenous hormone secreted by intestinal L-cells in response to food intake. It plays a central role in postprandial glucose regulation and satiety signaling. Its natural half-life is approximately 2 minutes — it's rapidly degraded by the enzyme DPP-4.
GLP-1 receptor activation produces several distinct effects:
- Appetite suppression — acts on hypothalamic receptors to reduce hunger perception
- Delayed gastric emptying — food moves through the stomach more slowly, prolonging satiety
- Glucose-dependent insulin secretion — stimulates insulin release only when glucose is elevated (reducing hypoglycemia risk)
- Glucagon suppression — reduces hepatic glucose output
- CNS satiety signaling — acts on brain reward and satiety circuits, reducing the hedonic drive to eat
The cumulative result: sustained caloric reduction through biological appetite regulation, not willpower.
What Semaglutide Is
Semaglutide is a synthetic GLP-1 receptor agonist engineered to mimic endogenous GLP-1 with dramatically extended duration. It shares ~94% amino acid sequence homology with native GLP-1, with modifications at positions 8 and 34 that confer resistance to DPP-4 degradation, plus a C18 fatty acid chain enabling albumin binding.
The result: a half-life of approximately 7 days, allowing once-weekly subcutaneous dosing at steady-state concentrations that native GLP-1 could never achieve.
FDA Approval Context
Semaglutide is FDA-approved under the brand names Ozempic (type 2 diabetes, 2017) and Wegovy (chronic weight management, 2021). The SUSTAIN and STEP trial programs established its efficacy across both indications with long-term safety data. This is one of the most clinically validated compounds in the GLP-1 class.
View Semaglutide + B12 (2.5mg/1mg) →
View Semaglutide + B12 (12.5mg/4mg) →
Why Titration Is Not Optional
Side effects from semaglutide are almost entirely gastrointestinal — nausea, vomiting, diarrhea, constipation — and they are dose-escalation dependent, not dose-dependent. Moving too fast through the titration schedule is the single most common reason people discontinue.
The pharmacokinetic logic: semaglutide reaches steady state after 4–5 weeks at any given dose level. Jumping doses before steady state is established overwhelms GI tolerance. Spending at least 4 weeks at each step allows adaptation and dramatically improves long-term adherence.
Reconstitution Math (15mg Vial)
| Step | Value |
|---|---|
| Vial size | 15 mg lyophilized |
| Bacteriostatic water added | 3.0 mL |
| Final concentration | 5.0 mg/mL |
| 1 unit (U-100 syringe) | = 50 mcg (0.05 mg) |
| 5 units | = 250 mcg (0.25 mg) |
| 10 units | = 500 mcg (0.5 mg) |
| 20 units | = 1.0 mg |
| 34 units | = 1.7 mg |
| 48 units | = 2.4 mg |
For doses under 10 units, use a 30- or 50-unit syringe for improved accuracy.
Standard Titration Protocol (Educational)
| Phase | Weekly Dose | Units (U-100) | Volume |
|---|---|---|---|
| Weeks 1–4 | 0.25 mg | 5 units | 0.05 mL |
| Weeks 5–8 | 0.5 mg | 10 units | 0.10 mL |
| Weeks 9–12 | 1.0 mg | 20 units | 0.20 mL |
| Weeks 13–16 | 1.7 mg | 34 units | 0.34 mL |
| Weeks 17+ (Maintenance) | 2.4 mg | 48 units | 0.48 mL |
Rules: same day each week, any time of day, with or without food. If GI side effects occur at any step — hold at current dose until tolerated, then proceed. Do not skip steps under any circumstances.
Semaglutide vs Traditional Fat Loss Approaches
| Factor | Caloric Restriction Alone | Stimulant-Based Fat Burners | Semaglutide (GLP-1) |
|---|---|---|---|
| Mechanism | Willpower-driven deficit | Sympathetic nervous system stimulation | Appetite biology regulation |
| Hunger suppression | None (increases hunger) | Mild/temporary | Strong, sustained |
| Metabolic adaptation | Significant — metabolism slows | Partial tolerance develops | Minimal — operates upstream of metabolism |
| Glycemic effect | None direct | None direct | Yes — improves insulin sensitivity |
| CNS reward circuit | Not addressed | Not addressed | Yes — reduces hedonic eating drive |
| Evidence base | Strong (but poor adherence) | Weak to moderate | Very strong (Phase 3 RCTs) |
| Long-term maintenance | Poor without behavioral change | Poor | Dependent on continued use |
The Muscle Preservation Issue
The most important practical caveat with GLP-1 therapy: weight loss includes lean mass. The STEP trials showed meaningful fat loss but also lean mass reduction — roughly 25–40% of total weight lost was lean tissue in some subgroups.
This is not a reason to avoid semaglutide. It's a reason to pair it with:
- Adequate protein intake — minimum 1.6–2.2g/kg body weight, maintained throughout
- Resistance training — the single most evidence-based intervention for preserving lean mass during a caloric deficit
- Tracking body composition, not just scale weight — DEXA or impedance measurement every 4–8 weeks
Semaglutide creates the caloric environment for fat loss. What you do in the gym and kitchen determines whether the weight lost is primarily fat or a mix of fat and muscle.
Storage Guidelines
| State | Temperature | Duration |
|---|---|---|
| Lyophilized (pre-reconstitution) | −20°C (−4°F) | Until expiry |
| Reconstituted | 2–8°C (refrigerated) | 28 days |
| Note | Protect from light. No freeze-thaw cycles after reconstitution. | |
Common Misconceptions
"It's just a shortcut — you still gain it all back." Weight regain after discontinuation is real and well-documented. But this is a pharmacokinetic reality about GLP-1 signaling, not a character flaw. Most medications for chronic conditions require ongoing use. The question is whether the risk-benefit profile justifies it — and for many patients, the data says yes.
"It kills your appetite completely." Semaglutide reduces appetite — it doesn't eliminate it. Most patients describe reduced hunger and earlier satiety, not complete disinterest in food. The dose determines the magnitude.
"You don't need to exercise on semaglutide." The data is clear: patients who combine GLP-1 therapy with resistance training preserve significantly more lean mass and achieve better body composition outcomes than those who rely on semaglutide alone.
"Higher dose = faster results." Escalating faster than the titration schedule doesn't improve outcomes — it increases GI side effects and dropout. The titration schedule is the protocol, not a suggestion.
References
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021. (STEP 1 Trial)
- Wadden TA, et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults with Overweight. JAMA. 2021. (STEP 3 Trial)
- Drucker DJ. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metab. 2018.
- Rubino DM, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity. JAMA. 2021. (STEP 4 Trial)
- Christou GA, et al. Semaglutide as a promising antiobesity drug. Obes Rev. 2019.
Educational Disclaimer: This content is for educational and informational purposes only. Semaglutide is an FDA-approved medication (Ozempic, Wegovy) for specific indications. This guide does not constitute medical advice or individualized treatment recommendations. Consult a qualified healthcare provider before using semaglutide or any GLP-1 therapy.
FitAF Performance — Educational content only.
